Home > > > > > Report Detail

Narcolepsy - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's ‘Narcolepsy - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Narcolepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

- The United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2016-2028

Narcolepsy Epidemiology

The Narcolepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Narcolepsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Narcolepsy Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, narcolepsy with and without cataplexy prevalent cases, prevalent cases by manifestations, diagnosed cases, age-specific diagnosed cases) scenario of Narcolepsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, total prevalent population of Narcolepsy in 7 major markets are about 507,138 in 2016.

Report Scope

- The report covers detailed overview of Narcolepsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- The report provides the insight about the historical and forecasted patient pool of Narcolepsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Report assesses the disease risk and burden and highlights the unmet needs of the disease

- The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

- The report provides the segmentation of the disease epidemiology by narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases in 7MM

Key strengths

- 10 Year Forecast of Narcolepsy epidemiology

- 7MM Coverage

- Total Prevalent Cases of Narcolepsy

- Prevalent Cases according to segmentation: Narcolepsy with and without cataplexy, cases by clinical manifestation and age-specific diagnosed cases

- Diagnosed cases of Narcolepsy

Key assessments

- Patient Segmentation

- Disease Risk & Burden

- Risk of disease by the segmentation

- Factors driving growth in a specific patient population

Narcolepsy - Epidemiology Forecast to 2028

Table of Contents

1. Key Insights
2. Disease Background and Overview: Narcolepsy
2.1. Introduction
2.2. Signs and Symptoms
2.3. Complications
2.4. Pathophysiology
2.5. Etiology
2.6. Risk Factors
2.7. Diagnosis
2.8. Treatment
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Population and Forecast Parameters
4. 7MM Total Prevalent Patient Population of Narcolepsy
4.1. United States
4.1.1. Prevalent Patient Population of Narcolepsy in the United States
4.1.2. Narcolepsy with and without Cataplexy Cases
4.1.3. Prevalent Cases by Clinical Manifestation
4.1.4. Diagnosed Cases of Narcolepsy
4.1.5. Age-Specific Diagnosed Cases of Narcolepsy
4.2. Germany
4.2.1. Prevalent Population of Narcolepsy
4.2.2. Narcolepsy cases with and without Cataplexy
4.2.3. Prevalent Cases by Clinical Manifestation
4.2.4. Diagnosed Cases of Narcolepsy
4.2.5. Age-Specific Diagnosed Cases of Narcolepsy
4.3. France
4.3.1. Prevalent Population of Narcolepsy
4.3.2. Narcolepsy cases with and without Cataplexy
4.3.3. Prevalent Cases by Clinical Manifestation
4.3.4. Diagnosed Cases of Narcolepsy
4.3.5. Age-Specific Diagnosed Cases of Narcolepsy
4.4. Italy
4.4.1. Prevalent Population of Narcolepsy in Italy
4.4.2. Narcolepsy cases with and without Cataplexy
4.4.3. Prevalent Cases by Clinical Manifestation
4.4.4. Diagnosed Cases of Narcolepsy
4.4.5. Age-Specific Diagnosed Cases of Narcolepsy
4.5. Spain
4.5.1. Prevalent Population of Narcolepsy
4.5.2. Narcolepsy cases with and without Cataplexy
4.5.3. Prevalent Cases by Clinical Manifestation
4.5.4. Diagnosed Cases of Narcolepsy
4.5.5. Age-Specific Diagnosed Cases of Narcolepsy
4.6. United Kingdom
4.6.1. Prevalent Cases of Narcolepsy
4.6.2. Narcolepsy cases with and without Cataplexy
4.6.3. Prevalent Cases by Clinical Manifestation
4.6.4. Diagnosed Cases of Narcolepsy
4.6.5. Age-Specific Diagnosed Cases of Narcolepsy
4.7. Japan
4.7.1. Prevalent Population of Narcolepsy
4.7.2. Narcolepsy cases with and without Cataplexy
4.7.3. Prevalent Cases by Clinical Manifestation
4.7.4. Diagnosed Cases of Narcolepsy
4.7.5. Age-Specific Diagnosed Cases of Narcolepsy
5. Market Drivers
6. Market Barriers
7. Appendix
8. Report Methodology
8.1. Sources Used
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

List of Tables

Table 1 Total Prevalent Patient Population of Narcolepsy in the 7MM (2016-2028)
Table 2 Prevalent Cases of Narcolepsy in the United States (2016-2028)
Table 3 Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Table 4 Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Table 5 Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Table 6 Age-Specific Diagnosed Cases of Narcolepsy in United States (2016-2028)
Table 7 Prevalent Cases of Narcolepsy in Germany (2016-2028)
Table 8 Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Table 9 Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Table 10 Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 11 Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Table 12 Prevalent Cases of Narcolepsy in France (2016-2028)
Table 13 Narcolepsy with and without Cataplexy cases in France (2016-2028)
Table 14 Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Table 15 Diagnosed Cases of Narcolepsy in France (2063-2028)
Table 16 Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Table 17 Prevalent Population of Narcolepsy in Italy (2016-2028)
Table 18 Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Table 19 Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Table 20 Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 21 Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Table 22 Prevalent Cases of Narcolepsy in Spain (2016-2028)
Table 23 Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Table 24 Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Table 25 Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 26 Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Table 27 Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 28 Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Table 29 Prevalent Cases of Narcolepsy by Clinical Manifestations in United Kingdom (2016-2028)
Table 30 Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 31 Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Table 32 Prevalent Cases of Narcolepsy in Japan (2016-2028)
Table 33 Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Table 34 Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Table 35 Diagnosed Cases of Narcolepsy in Japan (2016-2028)
Table 36 Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)

List of Figures

Figure 1: Complications of Narcolepsy
Figure 2: Pathophysiology of Narcolepsy
Figure 3: Prevalent Cases of Narcolepsy in the United States (2016-2028)
Figure 4: Narcolepsy with and without Cataplexy Cases in the United States (2016-2028)
Figure 5: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United States (2016-2028)
Figure 6: Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 7: Age-Specific Diagnosed Cases of Narcolepsy in the United States (2016-2028)
Figure 8:Prevalent Cases of Narcolepsy in Germany (2016-2028)
Figure 9: Narcolepsy with and without Cataplexy Cases in Germany (2016-2028)
Figure 10: Prevalent Cases of Narcolepsy by Clinical Manifestations in Germany (2016-2028)
Figure 11: Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 12: Age-Specific Diagnosed Cases of Narcolepsy in Germany (2016-2028)
Figure 13: Prevalent Cases of Narcolepsy in France (2016-2028)
Figure 14: Narcolepsy with and without Cataplexy cases in France (2016-2028)
Figure 15: Prevalent Cases of Narcolepsy by Clinical Manifestations in France (2016-2028)
Figure 16: Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 17: Age-Specific Diagnosed Cases of Narcolepsy in France (2016-2028)
Figure 18: Prevalent Population of Narcolepsy in Italy (2016-2028)
Figure 19: Narcolepsy with and without Cataplexy cases in Italy (2016-2028)
Figure 20: Prevalent Cases of Narcolepsy by Clinical Manifestations in Italy (2016-2028)
Figure 21: Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 22: Age-Specific Diagnosed Cases of Narcolepsy in Italy (2016-2028)
Figure 23: Prevalent Cases of Narcolepsy in Spain (2016-2028)
Figure 24: Narcolepsy with and without Cataplexy Cases in Spain (2016-2028)
Figure 25: Prevalent Cases of Narcolepsy by Clinical Manifestations in Spain (2016-2028)
Figure 26: Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 27: Age-Specific Diagnosed Cases of Narcolepsy in Spain (2016-2028)
Figure 28: Prevalent Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 29: Narcolepsy with and without Cataplexy cases in the United Kingdom (2016-2028)
Figure 30: Prevalent Cases of Narcolepsy by Clinical Manifestations in the United Kingdom (2016-2028)
Figure 31: Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 32: Age-Specific Diagnosed Cases of Narcolepsy in the United Kingdom (2016-2028)
Figure 33: Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 34: Narcolepsy with and without Cataplexy cases in Japan (2016-2028)
Figure 35: Prevalent Cases of Narcolepsy by Clinical Manifestations in Japan (2016-2028)
Figure 36: Total Prevalent Population of Narcolepsy in Japan (2016-2028)
Figure 37: Age-Specific Diagnosed Cases of Narcolepsy in Japan (2016-2028)

  • Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......
  • Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 110
    Report Overview: Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......
  • Global Epilepsy Therapeutics Market Research Report 2023
    Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Cephalon - Novartis - Pfizer - Johnson & Johnson - GlaxoSmithKline - Sanofi - Sunovion Pharmaceuticals......
  • Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Autism Spectrum Disorder market: According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......
  • Global Autism Spectrum Disorder Market Status and Outlook 2023-2028
    Published: 24-Nov-2023        Price: US 3160 Onwards        Pages: 109
    Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......
  • Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Epilepsy Therapeutics market: According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years. Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......
  • Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 98
    Market Overview of Global Gabapentin market: According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......
  • 2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel
    Published: 09-Oct-2023        Price: US 2500 Onwards        Pages: 89
    This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Aut......
  • Global Gabapentin Market Insights, Forecast to 2029
    Published: 27-Sep-2023        Price: US 4900 Onwards        Pages: 112
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs